Simvastatin induces breast cancer cell death through the deactivation of PI3K/Akt and MAPK/Erk signals (156) and also prevents triple-negative breast cancer proliferation and metastasis through Foxo3a phosphorylation (157) or HSP90 acetylation (158). This evidence concerns the gene AKT1 and breast cancer.